Match!

Discovery of Metabolic Biomarkers Predicting Radiation Therapy Late Effects in Prostate Cancer Patients.

Published on Jan 1, 2019in Advances in Experimental Medicine and Biology2.126
· DOI :10.1007/978-3-030-22254-3_11
Amrita K. Cheema22
Estimated H-index: 22
(GUMC: Georgetown University Medical Center),
Scott Grindrod8
Estimated H-index: 8
+ 12 AuthorsAnatoly Dritschilo48
Estimated H-index: 48
(MedStar Georgetown University Hospital)
Abstract
Patients presenting with prostate cancers undergo clinical staging evaluations to determine the extent of disease to guide therapeutic recommendations. Management options may include watchful waiting, surgery, or radiation therapy. Thus, initial risk stratification of prostate cancer patients is important for achieving optimal therapeutic results or cancer cure and preservation of quality of life. Predictive biomarkers for risks of complications or late effects of treatment are needed to inform clinical decisions for treatment selection. Here, we analyzed pre-treatment plasma metabolites in a cohort of prostate cancer patients (N = 99) treated with Stereotactic Body Radiation Therapy (SBRT) at Medstar-Georgetown University Hospital in a longitudinal, quality-of-life study to determine if individuals experiencing radiation toxicities can be identified by a molecular profile in plasma prior to treatment. We used a multiple reaction mass spectrometry-based molecular phenotyping of clinically annotated plasma samples in a retrospective outcome analysis to identify candidate biomarker panels correlating with adverse clinical outcomes following radiation therapy. We describe the discovery of candidate biomarkers, based on small molecule metabolite panels, showing high correlations (AUCs ≥ 95%) with radiation toxicities, suitable for validation studies in an expanded cohort of patients.
  • References (27)
  • Citations (0)
📖 Papers frequently viewed together
15 Citations
15 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References27
Newest
Prostate cancer is the most common non-cutaneous cancer among men in the United States. In the last decade there has been a rapid expansion in the field of biomarker assays for diagnosis, prognosis, and treatment prediction in prostate cancer. The evidence base for these assays is rapidly evolving. With several commercial assays available at each stage of the disease, deciding which genomic assays are appropriate for which patients can be nuanced for physicians. In an effort to help guide these ...
9 CitationsSource
#1Michael C. Repka (Georgetown University)H-Index: 4
#2Thomas P. KoleH-Index: 6
Last. Sean P. Collins (Georgetown University)H-Index: 45
view all 11 authors...
3 CitationsSource
#1Ima Paydar (Georgetown University)H-Index: 5
#2Robyn A. Cyr (Georgetown University)H-Index: 5
Last. Sean P. Collins (Georgetown University)H-Index: 45
view all 10 authors...
Background: Proctitis following prostate cancer radiation therapy is a primary determinant of quality of life (QOL). While previous studies have assessed acute rectal morbidity at 1 month after stereotactic body radiotherapy (SBRT), little data exist on the prevalence and severity of rectal morbidity within the first week following treatment. This study reports the acute bowel morbidity one week following prostate SBRT. Materials and methods: Between May 2013 and August 2014, 103 patients with c...
9 CitationsSource
#1Maverick W. K. Tsang (CUHK: The Chinese University of Hong Kong)H-Index: 2
Stereotactic body radiotherapy (SBRT) has emerged as the standard treatment for medically inoperable early-staged non-small cell lung cancer (NSCLC). The local control rate after SBRT is over 90%. Some forms of tumour motion management and image-guided radiation delivery techniques are the prerequisites for fulfilment of its goal to deliver a high radiation dose to the tumour target without overdosing surrounding normal tissues. In this review, the current strategies of tumour motion management ...
4 CitationsSource
#1Catherine E. Mercado (Georgetown University)H-Index: 2
#2Marie-Adele Sorel Kress (Georgetown University)H-Index: 5
Last. Sean P. Collins (Georgetown University)H-Index: 45
view all 14 authors...
Abstract: Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) is emerging as a minimally invasive alternative to brachytherapy to deliver highly conformal, dose-escalated radiation therapy to the prostate. SBRT alone may not adequately cover the tumor extensions outside the prostate commonly seen in unfavorable prostate cancer. External beam radiation therapy (EBRT) with high dose rate brachytherapy boost is a proven effective therapy for unfavorable prostate cancer. This study repo...
12 CitationsSource
#1Nicholas G. ZaorskyH-Index: 19
#2Scott W. KeithH-Index: 20
Last. Robert B. Den (Thomas Jefferson University)H-Index: 28
view all 7 authors...
Freedom from biochemical failure (FFBF) is a common primary outcome of randomized-controlled trials of prostate cancer (PCa). We aimed to determine how increasing the PCa biologically equivalent dose (BED) of external radiation therapy (RT) is correlated with FFBF and overall patient outcomes: overall survival (OS), distant metastasis (DM), and cancer-specific mortality (CSM); as well as genitourinary (GU), and gastrointestinal toxicities. We performed a meta-analysis of 6884 PCa patients from 1...
19 CitationsSource
#1Thomas P. Kole (Georgetown University)H-Index: 6
#2Michael Tong (Georgetown University)H-Index: 4
Last. Sean P. Collins (Georgetown University)H-Index: 45
view all 10 authors...
Background. Late urinary symptom flare has been shown to occur in a small subset of men treated with ultra- hypofractionated stereotactic body radiotherapy (SBRT) for prostate cancer. The purpose of this study was to use normal tissue complication probability modeling in an effort to derive SBRT specific dosimetric predictor's of late urinary flare.Material and methods. Two hundred and sixteen men were treated for localized prostate cancer using ultra- hypofractionated SBRT. A dose of 35–36.25 G...
16 CitationsSource
#1Matthew Foote (Princess Alexandra Hospital)H-Index: 15
#2Michael Bailey (UOW: University of Wollongong)H-Index: 2
Last. David Thwaites (USYD: University of Sydney)H-Index: 21
view all 10 authors...
The uptake of stereotactic ablative body radiation therapy (SABR)/stereotactic body radiation therapy (SBRT) worldwide has been rapid. The Australian and New Zealand Faculty of Radiation Oncology (FRO) assembled an expert panel of radiation oncologists, radiation oncology medical physicists and radiation therapists to establish guidelines for safe practice of SABR. Draft guidelines were reviewed by a number of international experts in the field and then distributed through the membership of the ...
16 CitationsSource
#1Einsley-Marie Janowski (Georgetown University)H-Index: 2
#2Thomas P. Kole (Georgetown University)H-Index: 6
Last. Sean P. Collins (Georgetown University)H-Index: 45
view all 10 authors...
Background: Dysuria following prostate radiation therapy is a common toxicity that adversely affects patients’ quality of life and may be difficult to manage. Methods: 204 patients treated with stereotactic body radiation therapy (SBRT) from 2007 to 2010 for localized prostate carcinoma with a minimum follow up of three years were included in this retrospective review of prospectively collected data. All patients were treated to 35-36.25Gy in 5 fractions delivered with robotic SBRT with real tim...
2 CitationsSource
#1Jennifer A. Woo (Georgetown University)H-Index: 5
#2Leonard N. Chen (Georgetown University)H-Index: 12
Last. Sean P. Collins (Georgetown University)H-Index: 45
view all 14 authors...
Purpose: Stereotactic body radiation therapy (SBRT) is increasingly utilized as primary treatment for clinically localized prostate cancer. Consensus regarding the appropriate patient-reported outcome (PRO) endpoints for clinical trials for early stage prostate cancer RT is lacking. To aid in trial design, this study presents PROs over 36 months following SBRT for clinically localized prostate cancer. Methods: 174 hormone-naive patients were treated with 35-36.25 Gy SBRT in 5 fractions. Patients...
10 CitationsSource
Cited By0
Newest